HOOKIPA Pharma Inc.

The news that Poolbeg Pharma is exploring a possible merger with Hookipa Pharma that would see the firm move its listing from London to the NASDAQ has excited their prospective boards but not gone dow

Esepapogene zalarnarepvec, Hookipa Pharma ’s investigational treatment for human papillomavirus 16-positive oropharyngeal cancer, is among the latest three products that have made it onto PRIME, the

The pace of new financings seems to be picking up in 2024 after a decline in the fourth quarter of 2023 relative to the last quarter of 2022, but some drug developers still are struggling to raise new

Roche Holding AG may have a challenger to approved KRAS G12C inhibitors after reporting data from a Phase I monotherapy study of divarasib (GDC-6036), which investigators reported in the New England